Navigation Links
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Date:6/17/2009

SAN MARINO, Calif., June 17 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs. The Fast Track Product designation, in particular, is granted following a critical evaluation of the "seriousness" or life-threatening nature of the unmet medical need, namely pancreatic cancer, and the potential of Rexin-G and its progressive clinical development to address this unmet need.

"This is an excellent affirmation of all that we have worked for," says Dr. Erlinda Maria Gordon, Medical Director of Epeius Biotechnologies, "and an important validation of our medical mission." Indeed, Rexin-G is the first in an entirely new class of targeted anti-cancer agents, with a sophistication that goes well beyond a simplistic antibody. Rexin-G is the flagship of tumor-targeted genetic medicine: "smart," "stealth," "selective" and "potent" nano-medicine that not only seeks out and accumulates in cancerous lesions that have spread throughout the body, but delivers a tumor-killing designer gene where it is needed most, selectively destroying tumor cells and their attendant blood supply, while sparing normal cells and healthy tissues. As presented at the 2009 ASCO G.I. Symposium, "Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer," documenting survival benefits, without toxicity, as monotherapy, when all else fails.

The FDA's timely decision to grant Rexin-G Fast Track Product Designation is not only validating in terms of the
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results
3. Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D
4. Veteran of the Beverage Industry, Ken Sadowsky, Joins Millennium Biotechnologies Board of Directors
5. MDS Analytical Technologies Acquires Blueshift Biotechnologies
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
10. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
11. Herzing University, Minneapolis Receives Board of Nursing Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... position as one of Medicare’s top-rated care centers in the country. To spread ... highlighting patient satisfaction and proving its facility is, indeed, worthy of five stars. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... Good Neighbor Pharmacy’s premier event and tradeshow, taking place July 29 to August ... purchasing decision makers. , ThoughtSpot is a four-day event for independent ...
(Date:6/30/2015)... ... 2015 , ... ADVOCATE, the premier provider of radiology revenue ... billing agreements with Jackson Radiology Associates in Jackson, TN. , ADVOCATE ... billing process software functionality called Experience Based Technology (EBTTM). EBTTM improves radiology ...
(Date:6/30/2015)... ... June 30, 2015 , ... After many ... , finally its here, http://www.express-glasses.com is proud to announce its collaboration ... ask about shipping with DHL Express when calling or visiting the express glasses ...
(Date:6/30/2015)... ... ... Dr. Sammy Masri of Masri Sports Medicine &Wellness, NJ Top Doc, is ... treatment of non-surgical sports and other musculoskeletal injuries for both adults and children, for ... exercise to stay healthy and active. Dr. Masri seeks to provide his patients with ...
Breaking Medicine News(10 mins):Health News:Villa Health Care Center Announces Highest Care Rating in New Video 2Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 2Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 3Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5
... ... a David versus Goliath struggle raging in the West, joins the stellar line-up ... York City and in Los Angeles (August 7 - 13). The film will ... the Reel Impact series on Planet Green, a network of Discovery Communications.,Split Estate ...
... , THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ... Drug Administration (FDA) announcement regarding the results of a safety ... (infliximab), Enbrel(R) (etanercept), Humira(R) (adalimumab), Cimzia(R) (certolizumab pegol) and Simponi(R) ...
... delivery was vaginal or C-section doesn,t matter, study finds ... anesthesia during a Cesarean delivery doesn,t increase the risk ... , "We found that the incidence of learning disabilities ... those who were delivered via C-section but with general ...
... such as Enbrel, Remicade , TUESDAY, Aug. 4 (HealthDay ... Crohn,s disease and other inflammatory disorders must now carry ... and doctors that the medicines may boost cancer risk ... Administration announced Tuesday. , The drugs, called tumor ...
... of the genetic material of tumor cells are switched off ... labeling ranges among the epigenetic changes that do not change ... particularly often in genes which act as important inhibitors of ... why healthy cells and cancer cells differ in their methylation ...
... , , KING OF PRUSSIA, Pa., Aug. 4 ... health insurers in America, announced a 28 percent drop in profit ... Bertolini, Aetna,s president, attributed the loss to "higher claim intensity, such ... and procedures per visit, resulting in higher costs for emergency room, ...
Cached Medicine News:Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 2Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 3Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 2Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 3Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 4Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 5Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 6Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 7Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 8Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 9Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 10Health News:Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 11Health News:No Link Found Between Birth Anesthesia and Learning Issues 2Health News:Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA 2Health News:Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA 3Health News:Silenced genes as a warning sign of blood cancer 2Health News:Aetna 28 Percent Profit Drop Signals Storm Clouds for Healthcare 2
(Date:6/30/2015)... Minn. , June 30, 2015  EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering  of 40,229,886 units. Each ... of a Series A warrant to purchase one share ... warrant to purchase one share of common stock, at ...
(Date:6/30/2015)... June 30, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... 2015 Annual Meeting of StockholdersWhen:Tuesday, June 30 at 5:10 ... the Internet.  Simply log onto our website listed above. ... during the live event, a replay of the webcast ... www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, INC. ...
(Date:6/29/2015)... , June 29, 2015  Daktari Diagnostics was honored ... the Technology in the Service of Society Award. IEEE President ... Barry L. Shoop presented the award to Principal ... The ceremony was held Saturday, June 20, 2015, at the ... . "I have spent more than ...
Breaking Medicine Technology:EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 2Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 3Daktari Honored with IEEE Spectrum Award 2
... leading provider of medical scrubs, is now accepting nominations through ... . The award provides the nation an opportunity to recognize ... duty to make a difference for their patients and the ... 9,000 healthcare professionals have been nominated for the award. To ...
... 2011 Wako Diagnostics, a division of Wako Chemicals ... and Drug Administration (FDA) to market the uTASWako i30 ... in vitro diagnostic (IVD) tests in the ... use by healthcare professionals as an aid in the ...
Cached Medicine Technology:Cherokee Inspired Comfort Award Calls for Healthcare Professional Nominations 2Cherokee Inspired Comfort Award Calls for Healthcare Professional Nominations 3Announcing 510(k) Clearance of a New Microfluidic-based IVD Test System, the uTASWako® i30 Immunoanalyzer, and AFP-L3 and DCP Assays for Liver Cancer Risk Assessment. 2
The URCA (Uric acid) method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of uric acid in serum, plasma and urine....
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
For the quantitative in vitro determination of Triglycerides in serum and plasma....
Medicine Products: